WAM
LSTA icon

Wolverine Asset Management’s Lisata Therapeutics LSTA Stock Holding History

Wolverine Asset Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-32
Closed -$26K – 2373
2014
Q3 		$26K Buy
32
+15
+88% +$13.1K ﹤0.01% 1730
2014
Q2 		$16K Buy
+17
New +$16.5K ﹤0.01% 1745

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Wolverine Asset Management's LSTA Position: Q4 2014 in Review

Wolverine Asset Management sold out of Lisata Therapeutics (LSTA) in Q4 2014, closing a stake of 32 shares — an estimated $26K sold.

Wolverine Asset Management first reported a position in LSTA in Q2 2014 and held it in 2 quarters. The position peaked at $26K in Q3 2014. 50 funds tracked by Wall St. Rank hold LSTA as of Q4 2014.

  • Wolverine Asset Management reported no remaining Lisata Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Wolverine Asset Management sold 32 Lisata Therapeutics shares in Q4 2014, an estimated $26K.
  • Wolverine Asset Management first reported a position in Lisata Therapeutics in Q2 2014 and held it in 2 quarters.
  • Wolverine Asset Management's Lisata Therapeutics position peaked at $26K in Q3 2014.
  • 50 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2014.

Based on Wolverine Asset Management's 13F filing for Q4 2014, filed 12 Feb 2015.